Ionis Pharmaceuticals (IONS)

Company Description

Ionis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company’s broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. IONS’ partner, Genzyme, plans to commercialize its lead product, Kynamro, in the U.S. and Europe following regulatory approval. IONS’ patents provide strong and extensive protection for its drugs and technology.

COMPANY ADDRESS
2855 Gazelle Court
Carlsbad, CA 92010
United States

COMPANY PHONE
760-931-9200

COMPANY WEBSITE



Get BioInvest's perspective on Ionis Pharmaceutical's CEO


Latest Company News

Ionis Pharmaceuticals, Inc. (IONS): Some of the key technical areas USA Commerce Daily - 6 hours ago With all other things going on, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has been on a free fall - declining -26.95 percent in just three months. [...]
Fri, Mar 24, 2017 7:18:00 PM, Continue reading at the source
Stock Volatility Risk Alert: Ionis Pharmaceuticals Inc Realized Volatility ... CML News - 12 hours ago Before we cover the full analysis we make a quick alert here that Ionis Pharmaceuticals Inc (NASDAQ:IONS) has seen its stock price whip around at an unsually high level. [...]
Fri, Mar 24, 2017 1:42:00 PM, Continue reading at the source
Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics Motley Fool - Mar 21, 2017 If you enjoy cutting-edge medicine, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Juno Therapeutics Inc (NASDAQ:JUNO) are two biotech stocks that belong on your radar. Analyst's Predictions on EQT Corporation (EQT), Ionis Pharmaceuticals, Inc. (IONS) - StockNewsJournal Hot Stock Update: Ionis Pharmaceuticals, Inc. (IONS) - HugoPress [...]
Tue, Mar 21, 2017 12:56:00 PM, Continue reading at the source
Ionis' Latest Attempt To Weaponize Antisense Against Cancer Seeking Alpha - Mar 15, 2017 Cancer-causing mutations in the KRAS gene have been studied for 30 years yet no direct inhibitor of mutant KRAS enzyme has entered clinical trials. FY2018 EPS Estimates for Ionis Pharmaceuticals Inc Lowered by Leerink Swann (IONS) - Chaffey Breeze The Ionis Pharmaceuticals Inc (IONS) Cut to “Sell” at Goldman Sachs Group Inc - Petro Global News 24 [...]
Wed, Mar 15, 2017 2:09:00 PM, Continue reading at the source
Ionis Exonerated, Buying Opportunity Created By Goldman Downgrade Seeking Alpha - Mar 13, 2017 Long-term investors should stiff-arm today's Goldman Sachs downgrade of Ionis Pharmaceuticals (NASDAQ:IONS) from Neutral to Sell because analyst Salveen Richter has ignored recent evidence exonerating the platform of alleged toxicity. [...]
Mon, Mar 13, 2017 1:00:00 PM, Continue reading at the source
Why Ionis Pharmaceuticals Is Tumbling 10% Today Motley Fool - Mar 10, 2017 What happened. After highly regarded investment firm Goldman Sachs cut its rating on the company, Ionis Pharmaceuticals (NASDAQ:IONS) shares dropped by more than 10% at 1:45 p.m. EST today. Ionis Pharmaceuticals Inc (IONS) Stock Dips on Goldman Sachs Downgrade - Investorplace.com Analyst Downgrades – Ionis Pharmaceuticals (NASDAQ:IONS) Stock Gets Downgraded ... - Market Exclusive [...]
Fri, Mar 10, 2017 7:34:00 PM, Continue reading at the source
Why Ionis Pharmaceuticals Rallied 12% in February Motley Fool - Mar 9, 2017 The company's volanesorsen phase 3 data was good enough for management to say it will advance it to the FDA. Investors should find out if IONIS-TTrx phase 3 trials were a success in Q2. Overall, Ionis Pharmaceuticals' target is to become profitable on ... Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen ... - PR Newswire (press release) Ionis Pharmaceuticals, Inc. (IONS): Checking the Chart - The USA Commerce [...]
Thu, Mar 09, 2017 9:40:00 PM, Continue reading at the source
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation ... PR Newswire (press release) - Mar 6, 2017 NEW YORK, March 6, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are ... [...]
Mon, Mar 06, 2017 7:30:00 PM, Continue reading at the source
Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money Motley Fool - Mar 1, 2017 Ionis Pharmaceuticals (NASDAQ:IONS) reported fourth-quarter earnings on Tuesday. The biotech has two drugs on the market, but given Kynamro's low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December, most of ... [...]
Wed, Mar 01, 2017 8:48:00 PM, Continue reading at the source
Company Update (NASDAQ:IONS): Here's Why Ionis Pharmaceuticals Inc Shares ... Smarter Analyst - Feb 28, 2017 Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments. Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings - Yahoo Finance Ionis Pharmaceuticals Inc. (IONS) Moves Higher on Volume Spike for March 03 - Equities.com [...]
Tue, Feb 28, 2017 2:03:00 PM, Continue reading at the source